Sanofi SA (SASY)

77.56
+0.12(+0.15%)
  • Volume:
    924,867
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    77.13 - 78.13
High dividend Yield

Dividend yield shows how much a company pays its shareholders in dividends annually per dollar invested. It reflects how much an investor will earn aside from any capital gains in the stock.

SASY Overview

Prev. Close
77.44
Day's Range
77.13-78.13
Revenue
52.87B
Open
77.81
52 wk Range
76.45-106.1
EPS
5.3
Volume
924,867
Market Cap
97.13B
Dividend (Yield)
3.33
(4.30%)
Average Vol. (3m)
2,084,734
P/E Ratio
18.43
Beta
0.363
1-Year Change
-5.09%
Shares Outstanding
1,254,049,766
Next Earnings Date
Oct 28, 2022
What is your sentiment on Sanofi?
or
Market is currently closed. Voting is open during market hours.

Sanofi SA News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Sanofi SA Analysis

Sanofi SA Company Profile

Sanofi SA Company Profile

Employees
95442
Market
France
  • Type:Equity
  • Market:France
  • ISIN:FR0000120578

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.

Read More

Analyst Price Target

Average108.38 (+39.74% Upside)
High130
Low69.76
Price77.56
No. of Analysts26
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellSellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • And after the downside due to GSK vaccine problem back in the beginning of August, here we have again Sanofi below 80€. Will it try to look for 75€? Will the removal of masks in public transport increase/decrease its share price? Will the supply chain crisis negatively affect the stock dragging it further down to 67€ covid level (around 2012 onwards lows?) That last question would mean PER decreasing to 15 level, while GSK PER is 14.80 and ROCHE is 21.19.
    0
    • what Is going on?
      0
      • they have been sied. They used to produce a OTC medicine that may cause cancer.
        0
    • huge results coming
      0
      • target price 110€ according to investir
        0
        • SASY is creating separate company Opella World Wide to separate CHC/OTC business. With standard business they may look for a merger. I think we could expect a merger with GSK.
          0
          • Indietro tutta con problemi legali!!!???
            0
            • Sanofi
              0
              • Vola occhio!!
                0
                • Sanofi Stuck as it’s not involved in the vaccine process; this is so disturbing
                  1
                  • Very good earnings, to the moonnnnnn
                    2